Beckman Coulter Diagnostics and Seegene Inc. have signed a Molecular Diagnostic assay supply agreement according to which Seegene will manufacture and supply reagents for Beckman Coulter’s VERIS MDx System, a new sample-to-answer molecular diagnostics instrument. Seegene Inc., a leading developer of multiplex PCR technologies, is dedicated to developing new technology for accurate diagnosis.

Beckman Coulter Diagnostics and Seegene Agreement

Beckman Coulter launched the VERIS MDx at the European Conference on Clinical Microbiology and Infectious Diseases (ECCMID) held in Barcelona in May 2014. This innovative fully automated random access molecular diagnostics system is designed for the quantitative and qualitative analysis of molecular targets from clinical patient specimens. VERIS integrates key steps in molecular diagnostics to streamline workflow and system management. By providing continuous access, one-step loading and individual test reporting, VERIS helps in the advancement and optimization of the molecular diagnostics lab with accurate and timely results.

The VERIS CMV assay is a Polymerase Chain Reaction (PCR) assay designed for the quantitative determination of CMV deoxyribonucleic acid (DNA) from human plasma. When used in conjunction with clinical presentation and other laboratory findings, the VERIS CMV assay helps in monitoring CMV viral load.

A world leader in the IVD industry, Beckman Coulter Diagnostics develops clinical diagnostic products that help advance and optimize the clinical laboratory. Beckman Coulter’s instruments, systems and tests help streamline processes to enhance efficiency, reduce costs and speed the delivery of results. Beckman Coulter is committed to the ongoing development of assays to expand the VERIS infectious disease portfolio. The VERIS MDx system and VERIS CMV assay received CE mark earlier this year.

Richard Creager, senior vice president of the MDx Business Unit and chief scientific officer at Beckman Coulter said, “We’re very excited to partner with Seegene and incorporate their novel and proprietary DPO, TOCE and MuDT technologies into our MDx solution. We expect to be able to quickly add to the menu we offer on VERIS with the Seegene Multiplex reagents that enable simultaneous and multiple detection and identification of various types of pathogens in a single test”.